Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Activity of ALY688 in Dry Eye Disease
NCT04201574Phase 2Completed
- Sponsor
- Allysta Pharmaceuticals
- Start
- Dec 2019
- Primary completion
- Sep 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ALY688 in dry eye disease (DED), sponsored by Allysta Pharmaceuticals. Started Dec 2019; status: completed.
02
Drugs
ALY688
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT04201574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04201574.